Sustained-release corticosteroid options. - Wikidata - wikimedia - TriplyDB

Sustained-release corticosteroid options.

Sustained-release corticosteroid options.

http://www.wikidata.org/entity/Q38241548

about

Ocular Complications of Diabetes and Therapeutic Approaches Diabetic Macular Edema Intraocular Implants for the Treatment of Autoimmune Uveitis Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials Effect of dexamethasone intravitreal implant in a corneal graft rejection.Recent developments in ocular drug delivery.Fluocinolone acetonide for the treatment of diabetic macular edema.Preparation of dexamethasone ophthalmic implants: a comparative study of in vitro release profiles.Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.Fluocinolone Implant Forceps: Instrument Modification for Enhanced Implant Insertion.Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema.Sustained-release Corticosteroids for Uveitis.Comparative Study of In Situ Loaded Antibody and PEG-Fab NIPAAM Gels.New Drugs and New Posterior Delivery Methods in CME.Management of chronic ocular sarcoidosis: challenges and solutions.

P2860

Q26749412-488D3FCF-1855-445A-A2F8-198C5A120FBE Q26749438-99681035-CACE-4FC2-BD29-73E6F382F334 Q26799168-FB5C34AC-9700-4866-99C4-F1F5C171C40A Q35594036-16BB0967-71C7-4C40-8812-792AB1C859C9 Q36832950-2438674C-E6EC-4BCE-A312-4669C8BBE83D Q38603354-9C80F6C9-3C18-40E6-86B2-8D30209BD874 Q38648612-0CE46044-BA1C-4256-9FA3-72A3A733E6C1 Q38903822-F94E3B73-CAEB-49CE-BAF1-7A6C1829562D Q39087808-5B2E2071-29B6-4AFA-B968-27491EE7F455 Q41644514-F36A0224-019E-402B-A68B-0280C3069321 Q42842562-64873F67-7555-40F0-88AE-172C902DC13C Q43497965-AAB5D55A-7EDD-48AB-985D-7FE02D22E3A6 Q47330134-DD158BFF-9B06-44F2-80A6-3A8F02287FE1 Q50073381-68B78D83-2AF6-4190-ADD3-C2A6094BDE47 Q52338865-F2A5C3A6-67C9-4F33-92C0-D9A7CCC50E98

P2860

Sustained-release corticosteroid options.

http://www.wikidata.org/entity/Q38241548

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Sustained-release corticosteroid options.

@en

type

label

Sustained-release corticosteroid options.

@en

prefLabel

Sustained-release corticosteroid options.

@en

P1433

Q38241548-A158C679-2A84-4D0A-91A9-219FAEA87B59

P1476

Q38241548-484BA936-9368-45DE-8731-6D5D0A246439

P2093

Q38241548-3F77516C-B9E4-40E4-A78D-024B376B07EC

Q38241548-4D075C8A-6508-444F-A7F0-D91308C63287

P2860

Q38241548-000CA6C0-C2C3-40C1-9794-006AEE748E8D

Q38241548-0055DE22-4A0F-4210-90D4-3B70A0F44D4E

Q38241548-0D426F99-EEFE-4896-8AFD-3B9BE75D56E5

Q38241548-11EEDA7C-B67C-446A-8C29-65CEBE998E5B

Q38241548-290BBBC7-7523-4AF9-B2AE-DCB27D5F5BA1

Q38241548-292B301D-93EC-494C-B2D6-FA83B9E0565F

Q38241548-38EF884F-F2A1-4510-87D2-6990042FC46F

Q38241548-3C8AEE3A-EAB0-4356-AB42-46030EBD6123

Q38241548-56BBEF74-A7F9-4FEF-8E3A-D843D9159FA4

Q38241548-5B59CA44-1A3F-4467-A10B-BFFACCB78B73

P304

Q38241548-AA500888-3C0E-4950-A0E1-58045A1C5533

P31

Q38241548-0DE83ED1-22AB-4FB7-A831-07C3CE495B2C

P356

Q38241548-1D084126-A657-4997-A5D1-9B51C03EB038

P478

Q38241548-F0FD2ED7-A164-4953-9BA3-4ADB79E06EA4

P50

Q38241548-DAC239A1-914B-4A1E-88CB-F9A97F158E6C

P577

Q38241548-C13BD911-7BF2-4537-BFE0-608C4EE4D689

P5875

Q38241548-7A3B3004-08C5-4969-92FD-3CA22725A015

P698

Q38241548-C526118A-CF22-4769-943C-2F43A28636BD

P932

Q38241548-510DC467-1D70-4D07-9002-F71D32F385B7

P356

P1433

Journal of Ophthalmology

P1476

Sustained-release corticosteroid options.

@en

P2093

Mariana Cabrera

http://www.w3.org/2001/XMLSchema#string

Steven Yeh

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.

Steroids and macular edema from retinal vein occlusion.

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.

Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion.

Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.

Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema.

P304

164692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/164692

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Thomas A. Albini

P577

2014-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264940669

http://www.w3.org/2001/XMLSchema#string

P698

25140246

http://www.w3.org/2001/XMLSchema#string

P932

4130028

http://www.w3.org/2001/XMLSchema#string